

WE CURRENTLY HAVE TRIALS RECRUITING THE FOLLOWING TUMOR TYPES:

DOGS - Osteosarcoma, mast cell tumors, transitional cell carcinoma (bladder)

OPEN TRIALS:

1. Tumor type: APPENDICULAR OSTEOSARCOMA

Trial: Standard of care vs. standard of care plus an investigational agent for the treatment of appendicular osteosarcoma.

This is a randomized clinical trial for dogs with newly diagnosed appendicular osteosarcoma sponsored by Morris Animal foundation and the National Cancer Institute. All dogs will receive standard of care therapy as a part of the trial. Once the standard of care treatment is completed, some dogs may receive an investigational agent. A screening visit to determine eligibility is required. The trial is **FUNDED**. *PI- Dr. Olya Smrkovski, opuretsk@utk.edu.*

2. Tumor type: CANINE MAST CELL TUMOR.

Trial: Kinavet (masitinib) for non-resectable canine mast cell tumors.

This is a double-blinded placebo-controlled trial of Kinavet vs. placebo in dogs with non-resectable mast cell tumors (2/3 of the dogs will receive Kinavet, 1/3 will receive placebo). Dogs cannot pre-treated with chemotherapy or radiation and should be off steroids for at least 3 weeks. **Must have gross disease**. A screening visit to determine eligibility is required. The trial is **FUNDED, including screening visit**. *PI- Dr. Olya Smrkovski, opuretsk@utk.edu.*

3. Tumor type: CANINE BLADDER TRANSITIONAL CELL CARCINOMA

Trial: Evaluating a novel optical imaging agent, fluorocoxib A, to detect cyclooxygenase-2 (COX-2) expressing cancers of bladder in female dogs.

COX-2 enzyme is highly present in cancer cells, but not in normal cells that makes an attractive target for detection of cancer. This study using fluorocoxib A in dogs with naturally occurring cancers will assist to identify tumors that would benefit from COX-2 targeted NSAIDs. In addition, this study will assist to translate this novel imaging agent into clinical applications for detection of cancer, as well for monitoring the early responses to therapy not only in dogs, but also in human patients. This trial includes **financial incentives** to the client. Patients may be enrolled undiagnosed and the trial will pay for biopsy for diagnosis. Patients must be off NSAIDs for 2 weeks before enrollment or biopsy. **Female dogs only**. Trial period is approximately 24 hours.

PI- Dr. Maria Cekanova, mcekanov@utk.edu

4. COMING SOON: NUTRITION IN CANINE LYMPHOMA

Contact information listed below is for the referring veterinarians. Please have your veterinarian email or call us if you are interested in a clinical trial.

Please note: For all trials, patients must be examined at UTCVM to determine eligibility. Clients are usually responsible for the initial examination fee for the first visit (currently \$132) and any tests required by the trial to determine eligibility. Be sure to inquire about funding for the trial of interest. **Please contact the Clinical Trials Coordinator Gina Galyon, LVMT at ggalyon@utk.edu, 865-755-8151 or 865-974-8387** for information prior to referral.

This information is also available on our website <http://www.vet.utk.edu/news/story/oncology-clinical-trials-at-university-of-tennessee-veterinary-medical-center.html>